🔗 Share this article

While the US proceeds with unprecedented revisions to its vaccination guidelines, a particular individual has surfaced in a surprising turn: Tracy Beth Høeg, a Danish American physician and epidemiologist who first made her name by casting doubt on Covid vaccinations during the global health crisis and has zeroed in on alleged fatalities after COVID-19 vaccination in her recent tenure at the FDA.

Proposed Shifts to Childhood Immunization Schedule

Health officials had intended to announce major revisions to the childhood immunization program in December, aligning the US with Denmark’s vaccine program, sources say – a significant shift that would place the US at odds with many the international standard with little proof for improved outcomes. The announcement has been postponed until the next year.

Instead of the director of the vaccine center, Tracy Beth Høeg is set to present at the meeting. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth person to lead the center this calendar year.

A Shift at the Agency

This interim role could signify a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Dr. Prasad solidify control at the regulatory agency – and it points to a renewed priority upon dismantling previously authorized immunizations at the FDA.

The new acting director has often pushed for discontinuing certain pediatric immunization guidelines in the US so as to align more similar to the Danish model, a country with comprehensive healthcare and a population roughly the size of the state of Wisconsin.

So far public appearances, she has continued to focus on immunizations – usually the domain of Prasad, head of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Questions Over Background

Høeg has no apparent track record in pharmaceutical research, regulation or management, which has been standard for previous leaders of the CBER. She has been employed at the FDA as a senior adviser to the commissioner and CBER since March.

“She appears not to have the requisite experience” for running the pharmaceutical oversight division, said a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She lacks experience in leading a large organization. She lacks background in drug approvals.”

Past heads of the center would “be deeply familiar with regulatory frameworks and the research of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Objectively, she lacks the type of experience that previous people who headed CBER have had.”

The drug center has an immense workload at the agency, Woodcock pointed out.

“The public just focuses on the novel medication approvals, but the generic drug division clears a multitude of off-brand pharmaceuticals. There’s a biosimilars program, OTC medication office and more, and all of those have to be looked after,” Woodcock said. “The responsibility you neglect, that is the part that I always told people is going to cause problems.”

Furthermore, a significant management aspect to the job, which oversees in excess of 5,000 personnel. “It is a massive leadership role, if you do it right,” she added.

Agency Reaction and Disputed Initiatives

Regarding questions about Dr. Høeg's credentials and whether this appointment represents greater collaboration among regulatory chiefs on immunizations, a representative said that the “concerns stem from incorrect assumptions”.

“This background aligns with the functions of her role,” the spokesperson stated, noting the time Dr. Høeg spent guiding the FDA commissioner on “drug safety and approval science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s controversial priority voucher program, a contentious expedited therapy clearance system that apparently worried her predecessors. “How are these medications being chosen for this voucher program? Who is making the calls?” Dr. Howard said. “There’s a lot of secrecy happening at the regulatory body right now.”

In general, he said, “the agency seems to be moving towards more relaxed rules of most medications, aside from immunizations.”

Established Past Work on Immunizations

With immunizations, Dr. Høeg has a clearer, if problematic, past, critics have noted. She released a research paper using unconfirmed public submissions to estimate the incidence of heart inflammation after Covid immunization. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who was said to have changed statistics to suggest Covid vaccines are riskier than they are.

Included in her “wish list” for the current federal leadership encompassed altering regulations for recently developed shots and halting “non-essential” vaccines, she remarked after the election on a online show. At the agency, Dr. Høeg has according to sources proposed barring teenage boys from getting Covid vaccinations.

“She’s an complete true believer who begins with her preconceived notions and reverse-engineers to accommodate the data in a very deceptive, untruthful fashion,” Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg joined fellow dissenters, {like|